Koronyo-Hamaoui Lab

The primary focus of the Koronyo-Hamaoui Laboratory is on early diagnosis and immune-based therapies for Alzheimer's disease (AD). A feasible noninvasive test to identify patients early on, which is essential for effective treatment, is an urgent unmet need. The Koronyo-Hamaoui Laboratory has shown, for the first time, that the hallmark pathology of AD, amyloid-β protein (Aβ) plaque, is present in the retina of human patients beginning at early stages. Furthermore, a unique approach has been developed in this lab to detect plaques in the retina of live rodent models by a noninvasive optical retinal imaging. This innovation unveils new possibilities for investigation of Alzheimer's pathology in the retina. It may also facilitate early diagnosis and noninvasive monitoring of disease progression.

A large body of evidence accumulated over the past years suggested that the peripheral immune system plays a critical role in repair and regeneration of the central nervous system. This lab has demonstrated that harnessing peripheral immunity in murine transgenic models of AD via immune-modulating antigens, such as glatiramer acetate and MOG45D loaded on dendritic cells, stimulated recruitment of monocytes to the brain. This immunization approach leads to a reduction of harmful inflammation, toxic Aβ and scar tissue pathology, while restoring neurogenesis and cognitive functions. The lab further explores possibilities of utilizing inflammatory monocyte enrichment and the use of angiotensin-converting enzyme (ACE) overexpression in monocytes to counter AD progression. The Koronyo-Hamaoui team seeks to further identify and characterize new immunological mechanisms that help attenuate AD progression.

Plaque Dynamics: Retinal Optical Imaging of Curcumin-labeled Plaques following Glatiramer Acetate Immune-Modulation treatment (Koronyo et al. Neurodegener. Dis. 2012)

From left to right: Dieu-Trang (Sandrine) Fuchs, MSc; Altan Rentsendorj, PhD; Maya Koronyo-Hamaoui, PhD; Yosef Koronyo, MSc, LLB; Julia Sheyn BSc; and Michelle Moyseyev, BSc.

Seated from left to right: Maya Koronyo-Hamaoui, PhD (PI), Altan Rentsendorj, PhD. Standing from left to right: Tania Turbati, Leah Zuroff, Songlin Li, PhD, Julia Sheyn.

The presence of Aβ deposition in postmortem retinas of definitive Alzheimer’s patients and in early-stage cases has been identified for the first time by the Koronyo-Hamaoui Laboratory. In addition, the team developed a noninvasive retinal imaging approach for detection of plaques in live animal models.


  • University of Southern California, Neuropathology: Carol Ann Miller, MD
  • University of Southern California, Neurosurgery, Ophthalmology, Pathology: David Hinton, MD, Ernesto Barron, PhD
  • University of California, Los Angeles: David Teplow, PhD
  • Emory University, Neurology: Allan Levey, MD, PhD
  • Western University, Pharmacology & Basic Medical Sciences: Sebastien Fuchs, MD, PhD
  • Weizmann Institute, Israel: Michal Schwartz, PhD
Meet Our Team

Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Koronyo-Hamaoui Laboratory, whose dedicated efforts lead to groundbreaking discoveries.

Lahiri S, Regis GC, Koronyo Y, Fuchs D-T, Sheyn J, Kim E, Mastali M, Van Eyk J, Rajput PS, Lyden PD, Black KL, Ely EW, Jones H, Koronyo-Hamaoui M.

Critical Care 23(1):63.

Hampel HJ, et al. … Koronyo-Hamaoui M, et al. … and Lista, S.

J of Alzheimer's Dis. 2018;64(s1): S47-S105.

Contact the Koronyo-Hamaoui Lab

Cedars-Sinai Maxine Dunitz Neurosurgical Institute
127 S. San Vicente Blvd.
Advanced Health Science Pavilion, Eighth Floor, Suite A8103
Los Angeles, CA 90048